[go: up one dir, main page]

CA2404040A1 - Traitement de tumeurs non solides chez des mammiferes au moyen d'antagonistes de recepteur de facteur de croissance endothelial vasculaire - Google Patents

Traitement de tumeurs non solides chez des mammiferes au moyen d'antagonistes de recepteur de facteur de croissance endothelial vasculaire Download PDF

Info

Publication number
CA2404040A1
CA2404040A1 CA002404040A CA2404040A CA2404040A1 CA 2404040 A1 CA2404040 A1 CA 2404040A1 CA 002404040 A CA002404040 A CA 002404040A CA 2404040 A CA2404040 A CA 2404040A CA 2404040 A1 CA2404040 A1 CA 2404040A1
Authority
CA
Canada
Prior art keywords
vegfr
antagonist
cells
radiation
vegf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002404040A
Other languages
English (en)
Inventor
Larry Witte
Shahin Rafii
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cornell Research Foundation Inc
ImClone LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2404040A1 publication Critical patent/CA2404040A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Cette invention concerne une méthode permettant d'inhiber la croissance de cellules de tumeurs non solides qui sont stimulées par un ligand de facteur de croissance endothélial vasculaire chez des patients humains. Cette méthode consiste à administrer à ces patients une dose efficace d'un antagoniste dudit récepteur dudit facteur de croissance endothélial vasculaire.
CA002404040A 2000-03-31 2001-03-30 Traitement de tumeurs non solides chez des mammiferes au moyen d'antagonistes de recepteur de facteur de croissance endothelial vasculaire Abandoned CA2404040A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US54077000A 2000-03-31 2000-03-31
US09/540,770 2000-03-31
PCT/US2001/010504 WO2001074296A2 (fr) 2000-03-31 2001-03-30 Traitement de tumeurs non solides chez des mammiferes au moyen d'antagonistes de recepteur de facteur de croissance endothelial vasculaire

Publications (1)

Publication Number Publication Date
CA2404040A1 true CA2404040A1 (fr) 2001-10-11

Family

ID=24156859

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002404040A Abandoned CA2404040A1 (fr) 2000-03-31 2001-03-30 Traitement de tumeurs non solides chez des mammiferes au moyen d'antagonistes de recepteur de facteur de croissance endothelial vasculaire

Country Status (10)

Country Link
EP (1) EP1436000A2 (fr)
JP (1) JP2004501070A (fr)
KR (1) KR20020087453A (fr)
AU (1) AU2001249736A1 (fr)
CA (1) CA2404040A1 (fr)
CZ (1) CZ20023518A3 (fr)
IL (1) IL151992A0 (fr)
RU (1) RU2002129574A (fr)
SK (1) SK15302002A3 (fr)
WO (1) WO2001074296A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL211125B1 (pl) 2000-09-11 2012-04-30 Novartis Vaccines & Diagnostic Pochodne chinolinonu jako inhibitory kinazy tyrozynowej, kompozycje je zawierające i ich zastosowanie
IL156306A0 (en) 2000-12-21 2004-01-04 Glaxo Group Ltd Pyrimidineamines as angiogenesis modulators
EP1416960A4 (fr) * 2001-07-13 2006-02-22 Imclone Systems Inc Anticorps diriges contre vegfr-1 pour traiter le cancer du sein
JP2005526506A (ja) 2002-03-04 2005-09-08 イムクローン システムズ インコーポレイティド Ｋｄｒに特異的なヒト抗体及びその利用
KR20050037585A (ko) 2002-08-23 2005-04-22 카이론 코포레이션 벤지미다졸 퀴놀리논 및 그들의 사용
US7825132B2 (en) * 2002-08-23 2010-11-02 Novartis Vaccines And Diagnostics, Inc. Inhibition of FGFR3 and treatment of multiple myeloma
BRPI0413876A (pt) 2003-08-29 2006-10-24 Pfizer tienopiridin-fenilacetamidas e seus derivados úteis como agentes antiangiogênicos
UA82577C2 (en) 2003-12-23 2008-04-25 Пфайзер Инк. Quinoline derivatives
KR102027603B1 (ko) 2011-11-02 2019-10-01 아펙시젠, 인코포레이티드 항-kdr 항체 및 사용 방법

Also Published As

Publication number Publication date
WO2001074296A3 (fr) 2004-05-06
RU2002129574A (ru) 2004-04-20
AU2001249736A1 (en) 2001-10-15
IL151992A0 (en) 2003-04-10
EP1436000A2 (fr) 2004-07-14
KR20020087453A (ko) 2002-11-22
SK15302002A3 (sk) 2004-06-08
WO2001074296A2 (fr) 2001-10-11
CZ20023518A3 (cs) 2004-04-14
JP2004501070A (ja) 2004-01-15

Similar Documents

Publication Publication Date Title
JP7301106B2 (ja) 線維芽増殖因子受容体２に対するモノクローナル抗体
US6811779B2 (en) Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
US9249220B2 (en) Human monoclonal antibody neutralizing vascular endothelial growth factor receptor and use thereof
US20090022716A1 (en) Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
US20020012663A1 (en) Treatment of refractory human tumors with epidermal growth factor receptor antagonists
CA2404040A1 (fr) Traitement de tumeurs non solides chez des mammiferes au moyen d'antagonistes de recepteur de facteur de croissance endothelial vasculaire
CN100457181C (zh) 用血管内皮生长因子受体拮抗剂抑制肿瘤生长的联合疗法
HK40045902A (en) Monoclonal antibodies to fibroblast growth factor receptor 2

Legal Events

Date Code Title Description
FZDE Discontinued